The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study

Active, not recruitingOBSERVATIONAL
Enrollment

825

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

January 31, 2026

Study Completion Date

October 31, 2026

Conditions
Pediatric Solid Tumor
Interventions
GENETIC

Genetic testing and GAIN report

All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.

Trial Locations (12)

10032

Columbia University Medical Center, New York

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

43205

Nationwide Children's Hospital, Columbus

60637

University of Chicago Comer Children's Hospital, Chicago

75390

University of Texas Southwestern Medical Center at Dallas, Dallas

80045

Children's Hospital Colorado, Aurora

84113

University of Utah Childrens Medical Center, Salt Lake City

94158

University of California San Francisco, San Francisco

98105

Seattle Children's Hospital, Seattle

02215

Boston Children's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT02520713 - The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study | Biotech Hunter | Biotech Hunter